Pharmacoscintigraphic Investigation Into the Absorption of Nevirapine When Released Into Different Parts of the Gastro-intestinal Tract in Healthy Males
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 27
- Registration Number
- NCT02191189
Observational Study in Patients With HIV Infection Type 1 After Switching to a Viramune®-Containing Therapy Regimen
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 147
- Registration Number
- NCT02191332
Antistax® in Patients With Chronic Venous Insufficiency
Phase 2
Completed
- Conditions
- Venous Insufficiency
- Interventions
- Drug: Antistax®, high doseDrug: PlaceboDrug: Antistax®, low dose
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 260
- Registration Number
- NCT02191280
Nintedanib in Volunteers With Hepatic Impairment Compared With Healthy Volunteers
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2016-02-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 33
- Registration Number
- NCT02191865
- Locations
- 🇩🇪
1199.200.49001 Boehringer Ingelheim Investigational Site, Kiel, Germany
Relative Bioavailability of Dextromethorphan Syrup in Comparison to Dextromethorphan Soft Pastilles in Healthy Male and Female Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT02191709
Observational Study With Antiretroviral Treated Patients Switching to Nevirapine Plus Two Nucleoside Reverse Transcriptase Inhibitor (NRTI) Regimens
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 55
- Registration Number
- NCT02191319
Pharmacokinetic Study of Seresis® in the Skin in Healthy Young Female Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Seresis®
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 8
- Registration Number
- NCT02191852
Clinical and Therapeutic Evaluation of the Infection by HIV/AIDS
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 442
- Registration Number
- NCT02191215
Pharmacokinetic-pharmacodynamic Assessment of Seresis® in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Seresis®Drug: Placebo
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 10
- Registration Number
- NCT02191787
Study to Determine the Ability of Seresis to Act as a Skin Protection Agent in Healthy Young Female Volunteers
Phase 2
Completed
- Conditions
- Healthy
- Interventions
- Drug: Seresis®Drug: Placebo
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT02191813